Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Obesity and inflammation markers in relation to leukocyte telomere length in a cross-sectional study of persons with Barrett's esophagus.

Hardikar S, Song X, Risques RA, Montine TJ, Duggan C, Blount PL, Reid BJ, Anderson GL, Kratz M, White E, Vaughan TL.

BMC Obes. 2015 Sep 10;2:32. doi: 10.1186/s40608-015-0063-3. eCollection 2015.

2.

High Goblet Cell Count Is Inversely Associated with Ploidy Abnormalities and Risk of Adenocarcinoma in Barrett's Esophagus.

Srivastava A, Golden KL, Sanchez CA, Liu K, Fong PY, Li X, Cowan DS, Rabinovitch PS, Reid BJ, Blount PL, Odze RD.

PLoS One. 2015 Jul 31;10(7):e0133403. doi: 10.1371/journal.pone.0133403. eCollection 2015.

3.

Assessment of Esophageal Adenocarcinoma Risk Using Somatic Chromosome Alterations in Longitudinal Samples in Barrett's Esophagus.

Li X, Paulson TG, Galipeau PC, Sanchez CA, Liu K, Kuhner MK, Maley CC, Self SG, Vaughan TL, Reid BJ, Blount PL.

Cancer Prev Res (Phila). 2015 Sep;8(9):845-56. doi: 10.1158/1940-6207.CAPR-15-0130. Epub 2015 Jun 30.

4.

Bacterial Composition of the Human Upper Gastrointestinal Tract Microbiome Is Dynamic and Associated with Genomic Instability in a Barrett's Esophagus Cohort.

Gall A, Fero J, McCoy C, Claywell BC, Sanchez CA, Blount PL, Li X, Vaughan TL, Matsen FA, Reid BJ, Salama NR.

PLoS One. 2015 Jun 15;10(6):e0129055. doi: 10.1371/journal.pone.0129055. eCollection 2015.

5.

Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma.

Buas MF, Levine DM, Makar KW, Utsugi H, Onstad L, Li X, Galipeau PC, Shaheen NJ, Hardie LJ, Romero Y, Bernstein L, Gammon MD, Casson AG, Bird NC, Risch HA, Ye W, Liu G, Corley DA, Blount PL, Fitzgerald RC, Whiteman DC, Wu AH, Reid BJ, Vaughan TL.

Carcinogenesis. 2014 Dec;35(12):2740-7. doi: 10.1093/carcin/bgu207. Epub 2014 Oct 3.

6.

Inflammation and oxidative stress markers and esophageal adenocarcinoma incidence in a Barrett's esophagus cohort.

Hardikar S, Onstad L, Song X, Wilson AM, Montine TJ, Kratz M, Anderson GL, Blount PL, Reid BJ, White E, Vaughan TL.

Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2393-403. doi: 10.1158/1055-9965.EPI-14-0384. Epub 2014 Aug 8.

7.

Intraindividual variability over time in plasma biomarkers of inflammation and effects of long-term storage.

Hardikar S, Song X, Kratz M, Anderson GL, Blount PL, Reid BJ, Vaughan TL, White E.

Cancer Causes Control. 2014 Aug;25(8):969-76. doi: 10.1007/s10552-014-0396-0. Epub 2014 May 17.

8.

Quantification of population benefit in evaluation of biomarkers: practical implications for disease detection and prevention.

Li X, Blount PL, Reid BJ, Vaughan TL.

BMC Med Inform Decis Mak. 2014 Mar 6;14:15. doi: 10.1186/1472-6947-14-15.

9.

Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus.

Li X, Galipeau PC, Paulson TG, Sanchez CA, Arnaudo J, Liu K, Sather CL, Kostadinov RL, Odze RD, Kuhner MK, Maley CC, Self SG, Vaughan TL, Blount PL, Reid BJ.

Cancer Prev Res (Phila). 2014 Jan;7(1):114-27. doi: 10.1158/1940-6207.CAPR-13-0289. Epub 2013 Nov 19.

10.

NSAIDs modulate clonal evolution in Barrett's esophagus.

Kostadinov RL, Kuhner MK, Li X, Sanchez CA, Galipeau PC, Paulson TG, Sather CL, Srivastava A, Odze RD, Blount PL, Vaughan TL, Reid BJ, Maley CC.

PLoS Genet. 2013 Jun;9(6):e1003553. doi: 10.1371/journal.pgen.1003553. Epub 2013 Jun 13.

11.

Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma.

Duggan C, Onstad L, Hardikar S, Blount PL, Reid BJ, Vaughan TL.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):934-43. doi: 10.1016/j.cgh.2013.02.017. Epub 2013 Mar 1.

12.

The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagus.

Hardikar S, Onstad L, Blount PL, Odze RD, Reid BJ, Vaughan TL.

PLoS One. 2013;8(1):e52192. doi: 10.1371/journal.pone.0052192. Epub 2013 Jan 3.

13.

Selenium, selenoenzymes, oxidative stress and risk of neoplastic progression from Barrett's esophagus: results from biomarkers and genetic variants.

Takata Y, Kristal AR, Santella RM, King IB, Duggan DJ, Lampe JW, Rayman MP, Blount PL, Reid BJ, Vaughan TL, Peters U.

PLoS One. 2012;7(6):e38612. doi: 10.1371/journal.pone.0038612. Epub 2012 Jun 8.

14.

Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus.

Kantor ED, Onstad L, Blount PL, Reid BJ, Vaughan TL.

Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):456-61. doi: 10.1158/1055-9965.EPI-11-1014. Epub 2012 Jan 12.

15.

Application of biomarkers in cancer risk management: evaluation from stochastic clonal evolutionary and dynamic system optimization points of view.

Li X, Blount PL, Vaughan TL, Reid BJ.

PLoS Comput Biol. 2011 Feb;7(2):e1001087. doi: 10.1371/journal.pcbi.1001087. Epub 2011 Feb 24.

16.

A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma.

Merlo LM, Shah NA, Li X, Blount PL, Vaughan TL, Reid BJ, Maley CC.

Cancer Prev Res (Phila). 2010 Nov;3(11):1388-97. doi: 10.1158/1940-6207.CAPR-10-0108. Epub 2010 Oct 12.

17.

Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma.

Paulson TG, Maley CC, Li X, Li H, Sanchez CA, Chao DL, Odze RD, Vaughan TL, Blount PL, Reid BJ.

Clin Cancer Res. 2009 May 15;15(10):3305-14. doi: 10.1158/1078-0432.CCR-08-2494. Epub 2009 May 5.

18.

Intestinal differentiation in metaplastic, nongoblet columnar epithelium in the esophagus.

Hahn HP, Blount PL, Ayub K, Das KM, Souza R, Spechler S, Odze RD.

Am J Surg Pathol. 2009 Jul;33(7):1006-15. doi: 10.1097/PAS.0b013e31819f57e9.

19.

Nonadenomatous dysplasia in barrett esophagus: a clinical, pathologic, and DNA content flow cytometric study.

Rucker-Schmidt RL, Sanchez CA, Blount PL, Ayub K, Li X, Rabinovitch PS, Reid BJ, Odze RD.

Am J Surg Pathol. 2009 Jun;33(6):886-93. doi: 10.1097/PAS.0b013e318198a1d4.

20.

Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression.

Li X, Galipeau PC, Sanchez CA, Blount PL, Maley CC, Arnaudo J, Peiffer DA, Pokholok D, Gunderson KL, Reid BJ.

Cancer Prev Res (Phila). 2008 Nov;1(6):413-23. doi: 10.1158/1940-6207.CAPR-08-0121.

21.

p16 mutation spectrum in the premalignant condition Barrett's esophagus.

Paulson TG, Galipeau PC, Xu L, Kissel HD, Li X, Blount PL, Sanchez CA, Odze RD, Reid BJ.

PLoS One. 2008;3(11):e3809. doi: 10.1371/journal.pone.0003809. Epub 2008 Nov 27.

22.

Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study.

Chao DL, Sanchez CA, Galipeau PC, Blount PL, Paulson TG, Cowan DS, Ayub K, Odze RD, Rabinovitch PS, Reid BJ.

Clin Cancer Res. 2008 Nov 1;14(21):6988-95. doi: 10.1158/1078-0432.CCR-07-5063.

23.

Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study.

Dong LM, Kristal AR, Peters U, Schenk JM, Sanchez CA, Rabinovitch PS, Blount PL, Odze RD, Ayub K, Reid BJ, Vaughan TL.

Nutr Cancer. 2008;60(1):39-48. doi: 10.1080/01635580701586762.

24.

Leukocyte telomere length predicts cancer risk in Barrett's esophagus.

Risques RA, Vaughan TL, Li X, Odze RD, Blount PL, Ayub K, Gallaher JL, Reid BJ, Rabinovitch PS.

Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2649-55.

25.

Longitudinal study of insulin-like growth factor, insulin-like growth factor binding protein-3, and their polymorphisms: risk of neoplastic progression in Barrett's esophagus.

Siahpush SH, Vaughan TL, Lampe JN, Freeman R, Lewis S, Odze RD, Blount PL, Ayub K, Rabinovitch PS, Reid BJ, Chen C.

Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2387-95.

26.

Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus.

Srivastava A, Hornick JL, Li X, Blount PL, Sanchez CA, Cowan DS, Ayub K, Maley CC, Reid BJ, Odze RD.

Am J Gastroenterol. 2007 Mar;102(3):483-93; quiz 694.

PMID:
17338734
27.

NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.

Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD, Ayub K, Rabinovitch PS, Vaughan TL, Reid BJ.

PLoS Med. 2007 Feb;4(2):e67.

28.

Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus.

Glickman JN, Blount PL, Sanchez CA, Cowan DS, Wongsurawat VJ, Reid BJ, Odze RD.

Hum Pathol. 2006 Oct;37(10):1304-15. Epub 2006 Jul 20.

PMID:
16949933
29.

Chromosomal instability in Barrett's esophagus is related to telomere shortening.

Finley JC, Reid BJ, Odze RD, Sanchez CA, Galipeau P, Li X, Self SG, Gollahon KA, Blount PL, Rabinovitch PS.

Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1451-7.

30.

Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.

Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL Jr, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK; AACR Task Force on Cancer Prevention.

Clin Cancer Res. 2006 Jun 15;12(12):3661-97. Review.

31.

Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort.

Lomo LC, Blount PL, Sanchez CA, Li X, Galipeau PC, Cowan DS, Ayub K, Rabinovitch PS, Reid BJ, Odze RD.

Am J Surg Pathol. 2006 Apr;30(4):423-35.

PMID:
16625087
32.

Genetic clonal diversity predicts progression to esophageal adenocarcinoma.

Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, Paulson TG, Blount PL, Risques RA, Rabinovitch PS, Reid BJ.

Nat Genet. 2006 Apr;38(4):468-73. Epub 2006 Mar 26.

PMID:
16565718
33.

Neosquamous epithelium does not typically arise from Barrett's epithelium.

Paulson TG, Xu L, Sanchez C, Blount PL, Ayub K, Odze RD, Reid BJ.

Clin Cancer Res. 2006 Mar 15;12(6):1701-6.

34.

Genetic mechanisms of TP53 loss of heterozygosity in Barrett's esophagus: implications for biomarker validation.

Wongsurawat VJ, Finley JC, Galipeau PC, Sanchez CA, Maley CC, Li X, Blount PL, Odze RD, Rabinovitch PS, Reid BJ.

Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):509-16.

35.

Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study.

Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, Rabinovitch PS, Reid BJ.

Lancet Oncol. 2005 Dec;6(12):945-52.

PMID:
16321762
36.

Low-fat, high fruit and vegetable diets and weight loss do not affect biomarkers of cellular proliferation in Barrett esophagus.

Kristal AR, Blount PL, Schenk JM, Sanchez CA, Rabinovitch PS, Odze RD, Standley J, Vaughan TL, Reid BJ.

Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2377-83.

37.

Biologic properties of columnar epithelium underneath reepithelialized squamous mucosa in Barrett's esophagus.

Hornick JL, Blount PL, Sanchez CA, Cowan DS, Ayub K, Maley CC, Reid BJ, Odze RD.

Am J Surg Pathol. 2005 Mar;29(3):372-80.

PMID:
15725807
38.

The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma.

Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Blount PL, Reid BJ.

Cancer Res. 2004 Oct 15;64(20):7629-33.

39.

Biomarkers in Barrett's esophagus.

Reid BJ, Blount PL, Rabinovitch PS.

Gastrointest Endosc Clin N Am. 2003 Apr;13(2):369-97. Review.

PMID:
12916666
40.

Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus.

Rudolph RE, Vaughan TL, Kristal AR, Blount PL, Levine DS, Galipeau PC, Prevo LJ, Sanchez CA, Rabinovitch PS, Reid BJ.

J Natl Cancer Inst. 2003 May 21;95(10):750-7.

41.

Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus.

Vaughan TL, Kristal AR, Blount PL, Levine DS, Galipeau PC, Prevo LJ, Sanchez CA, Rabinovitch PS, Reid BJ.

Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):745-52.

42.

Transcriptional analyses of Barrett's metaplasia and normal upper GI mucosae.

Barrett MT, Yeung KY, Ruzzo WL, Hsu L, Blount PL, Sullivan R, Zarbl H, Delrow J, Rabinovitch PS, Reid BJ.

Neoplasia. 2002 Mar-Apr;4(2):121-8.

43.

Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables.

Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ.

Am J Gastroenterol. 2001 Nov;96(11):3071-83.

44.

p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium.

Wong DJ, Paulson TG, Prevo LJ, Galipeau PC, Longton G, Blount PL, Reid BJ.

Cancer Res. 2001 Nov 15;61(22):8284-9.

45.

Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.

Reid BJ, Prevo LJ, Galipeau PC, Sanchez CA, Longton G, Levine DS, Blount PL, Rabinovitch PS.

Am J Gastroenterol. 2001 Oct;96(10):2839-48.

46.

A low-cost fiber-optic instrument to colorimetrically detect patients with Barrett's esophagus for early detection of esophageal adenocarcinoma.

Dattamajumbar AK, Blount PL, Myers JA, Proctor AH, Goldman BH, Reid BJ, Martin RW.

IEEE Trans Biomed Eng. 2001 Jun;48(6):695-705.

PMID:
11396599
47.

Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia.

Reid BJ, Blount PL, Feng Z, Levine DS.

Am J Gastroenterol. 2000 Nov;95(11):3089-96.

PMID:
11095322
48.

Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets.

Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS.

Am J Gastroenterol. 2000 Jul;95(7):1669-76.

49.

Safety of a systematic endoscopic biopsy protocol in patients with Barrett's esophagus.

Levine DS, Blount PL, Rudolph RE, Reid BJ.

Am J Gastroenterol. 2000 May;95(5):1152-7.

PMID:
10811320
50.

p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia.

Neshat K, Sanchez CA, Galipeau PC, Blount PL, Levine DS, Joslyn G, Reid BJ.

Gastroenterology. 1994 Jun;106(6):1589-95.

PMID:
8194706

Supplemental Content

Loading ...
Support Center